Basilea Pharmaceutica (SIX: BSLN)

Last close As at 21/12/2024

CHF41.60

−0.05 (−0.12%)

Market capitalisation

CHF548m

Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.

Latest Insights

View More
misael-moreno-fN6K30xtiKE-unsplash-Basilea

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free